NYSE$TEVA
Teva Pharmaceutical Industries ADR · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Teva's financial performance showed revenue growth and strategic progress.
Teva Pharmaceutical Industries reported a solid performance for Q2 2023, with revenues of $3.9 billion, a 4% increase in local currency terms, and a rise in non-GAAP gross margin. The company slightly increased its revenue guidance midpoint for the year and reaffirmed other guidance items, driven by growth from AUSTEDO and the launch of UZEDY.
- Revenues reached $3.9 billion, reflecting a 4% increase compared to Q2 2022 in local currency terms.
- Non-GAAP gross margin improved by 3.1 percentage points compared to Q1 2023.
- AUSTEDO experienced strong growth, contributing to the overall revenue increase.
- Successful launch of UZEDY, adding to the innovative product portfolio.
Headline financials
Revenue & EPS history
Teva · Revenue · Quarterly
$3.88B
Revenue by segment
Teva · $1.89B total across 3 segments · Q2 2023
- Europe$1.16B-0.7%61.6%
- International Markets$479M+5.5%25.4%
- Other Activities$245M-4.7%13.0%
Forward guidance
Teva revised its 2023 revenue outlook to $15.0-$15.4 billion, with all other key components reaffirmed.
Tailwinds
- Revenues: $15.0 – $15.4 billion
- Operating Income: $4.0 – $4.4 billion
- Adjusted EBITDA: $4.5 - $4.9 billion
- Diluted EPS: $2.25 – $2.55
- Free Cash Flow: $1.7 – $2.1 billion
Headwinds
- Finance Expenses: ~$1,000 million
- Tax Rate: 14% – 17%
- CAPEX: $0.5 billion
- Foreign Exchange: Volatile swings in FX can negatively impact revenue and income
- COPAXONE revenues are expected to be around $500 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.3%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.7%
Avg return
30 days after
51%
38 / 74 earnings
Positive
+27.1%
Q2 2022
Best reaction
-34.1%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.9% | +11.7% | |
| Q4 2025 | +2.1% | +9.2% | +4.1% | |
| Q3 2025 | +20.4% | +18.6% | +39.1% | |
| Q2 2025 | +1.8% | -5.1% | +11.1% | |
| Q1 2025 | +8.9% | +11.4% | +10.2% | |
| Q4 2024 | -13.9% | -19.4% | -23.5% | |
| Q3 2024 | -6.8% | -7.5% | -7.7% | |
| Q2 2024 | +6.9% | +1.6% | +15.0% | |
| Q1 2024 | +14.7% | +21.0% | +20.6% | |
| Q4 2023 | +6.2% | +5.5% | +15.1% | |
| Q3 2023 | -3.0% | -2.4% | +8.6% | |
| Q2 2023 | +15.4% | +16.2% | +18.7% | |
| Q1 2023 | -9.8% | -11.3% | -19.5% | |
| Q4 2022 | -9.8% | -5.4% | -16.3% | |
| Q3 2022 | -3.3% | +3.7% | -1.1% | |
| Q2 2022 | +27.1% | +30.5% | +37.6% | |
| Q1 2022 | -2.3% | -8.1% | +11.6% | |
| Q4 2021 | +6.3% | +2.8% | -9.8% | |
| Q3 2021 | -7.0% | -1.7% | -9.6% | |
| Q2 2021 | +8.6% | +10.4% | +4.8% | |
| Q1 2021 | +2.6% | +4.2% | +0.3% | |
| Q4 2020 | -11.8% | -13.2% | -15.8% | |
| Q3 2020 | -1.0% | +4.5% | +11.6% | |
| Q2 2020 | +3.0% | +0.6% | -22.1% | |
| Q1 2020 | +7.7% | +9.0% | +22.5% | |
| Q4 2019 | +1.9% | -0.9% | -31.9% | |
| Q3 2019 | +14.8% | +18.6% | +22.5% | |
| Q2 2019 | +3.3% | -0.6% | -0.7% | |
| Q1 2019 | -0.3% | -4.1% | -43.2% | |
| Q4 2018 | -9.6% | -6.0% | -13.7% | |
| Q3 2018 | +13.1% | +15.6% | +7.8% | |
| Q2 2018 | -7.1% | -2.5% | -4.0% | |
| Q1 2018 | -4.1% | +1.6% | +17.7% | |
| Q4 2017 | -10.7% | -11.2% | -8.0% | |
| Q3 2017 | -18.7% | -16.6% | +8.8% | |
| Q2 2017 | -34.1% | -16.2% | -39.4% | |
| Q1 2017 | +1.7% | +1.3% | -3.6% | |
| Q4 2016 | +8.4% | +9.4% | +6.7% | |
| Q3 2016 | -7.2% | -6.0% | -10.5% | |
| Q2 2016 | +1.2% | -6.2% | -8.8% | |
| Q1 2016 | +5.2% | +1.7% | +10.8% | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -5.1% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +0.1% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q2 2014 | -1.6% | — | — | |
| Q1 2014 | +2.0% | — | — | |
| Q4 2013 | -1.9% | — | — | |
| Q3 2013 | -1.5% | — | — | |
| Q2 2013 | -2.0% | — | — | |
| Q1 2013 | +1.0% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | -3.3% | — | — | |
| Q1 2012 | -5.4% | — | — | |
| Q4 2011 | +2.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q2 2011 | +1.9% | — | — | |
| Q1 2011 | +5.6% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | +0.3% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q1 2010 | +0.9% | — | — | |
| Q4 2007 | +1.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -1.4% | — | — | |
| Q3 2009 | -1.4% | — | — | |
| Q2 2008 | -0.8% | — | — | |
| Q2 2009 | -0.8% | — | — | |
| Q1 2009 | -0.6% | — | — | |
| Q1 2008 | -0.6% | — | — | |
| Q4 2008 | -0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro